Condition: Metastatic NSCLC · Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Immunotherapeutic approaches recently have demonstrated clinical efficacy in several cancer types, including melanoma and NSCLC. As a matter of fact, first registration trials of immune-checkpoints inhibitors (ICI) in second-line settings (pembrolizumab as well as nivolumab or atezolizumab) had stated that ICI could be continued until disease progression or not tolerable toxicity, up to 5 years. This is only for the first-line registration studies that the arbitrary maximal duration of treatment of 2 years was set up by the Companies sponsoring such trials. The aim is to study a de-escalation scheme of treatment from 2 years of immunotherapy to 6 months (27-weeks), in patients with controlled disease.
This description comes directly from the study's public registry record.
Clinical Operations Manager · 0156811046 · contact@ifct.fr
Always discuss trial participation with your own doctor first.
| Aix-en-Provence - CH | Aix-en-Provence, France | Not Yet Recruiting |
| Amiens - Clinique de l'Europe | Amiens, France | Not Yet Recruiting |
| Angers - CHU | Angers, France | Not Yet Recruiting |
| Avignon - CH | Avignon, France | Not Yet Recruiting |
| Besançon - CHU | Besançon, France | Not Yet Recruiting |
| Bordeaux - Polyclinique | Bordeaux, France | Not Yet Recruiting |
| CHU de Bordeaux | Bordeaux, France | Not Yet Recruiting |
| Caen - CHU Côte de Nacre | Caen, France | Recruiting |
| Cannes - CH | Cannes, France | Not Yet Recruiting |
| Chauny - Centre Hospitalier | Chauny, France | Not Yet Recruiting |
| CH | Colmar, France | Not Yet Recruiting |
| Centre Georges François Leclerc | Dijon, France | Not Yet Recruiting |
+ 32 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05255302